Venous (stasis) ulceration of the lower extremity is a problem of ever-increasing magnitude in the United States. Most patients are elderly and two thirds are women. Venous ulcers incapacitate the elderly and add to their frailty. An established treatment for venous ulcers is the application of leg compression bandages, such as the Unna boot, which reduce lower extremity venous hypertension by enhancing the action of the calf muscle pump. Recently, it has been proposed that venous hypertension causes the formation of pericapillary fibrin cuffs, which result in ulceration by interfering with the proper exchange of oxygen and other nutrients between blood and dermis. More recent evidence suggests that fibrin may bind to or render unavailable specific growth-regulatory peptides. The pathogenic role of fibrin is still not clear, but the presence of tissue hypoxia, profound alterations of systemic fibrinolysis, and dermal pericapillary fibrin cuffs in patients with venous ulcers are well established. Stanozolol, an anabolic steroid with fibrinolytic properties, has been reported to improve venous disease and ulcers caused by intravascular fibrin deposition. By increasing muscle mass, stanozolol also has the potential to improve lower extremity strength and the function of the calf muscle pump. The hypothesis of this proposal is that stanozolol can improve venous disease and frailty in elderly patients due to its positive effects on both muscle strength and fibrin degradation. We propose a randomized, double-blind, 24-week trial of orally administered stanozolol vs placebo in elderly patients with venous ulcers. The primary objective will be to determine the therapeutic effect and safety of stanozolol in ulcer healing. We will also investigate the effects of stanozolol on lower extremity muscle strength, calf muscle pump action, and somatomedin levels. The fibrinolytic action of stanozolol will be assessed by measurements of fibrinogen, D-dimer, and tissue plasminogen activator. It is hoped that these studies will establish stanozolol as an effective and rational treatment for ulcer healing and physical frailty in elderly patients with venous ulcers.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
3R01AG010998-03S1
Application #
2052205
Study Section
Biological and Clinical Aging Review Committee (BCA)
Project Start
1992-09-01
Project End
1997-06-30
Budget Start
1995-09-30
Budget End
1997-06-30
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Miami School of Medicine
Department
Dermatology
Type
Schools of Medicine
DUNS #
City
Miami
State
FL
Country
United States
Zip Code
33146
Falanga, V; Greenberg, A S; Zhou, L et al. (1998) Stimulation of collagen synthesis by the anabolic steroid stanozolol. J Invest Dermatol 111:1193-7
Weiss, E; Yamaguchi, Y; Falabella, A et al. (1998) Un-cross-linked fibrin substrates inhibit keratinocyte spreading and replication: correction with fibronectin and factor XIII cross-linking. J Cell Physiol 174:58-65
Tallman, P; Muscare, E; Carson, P et al. (1997) Initial rate of healing predicts complete healing of venous ulcers. Arch Dermatol 133:1231-4
Murata, H; Zhou, L; Ochoa, S et al. (1997) TGF-beta3 stimulates and regulates collagen synthesis through TGF-beta1-dependent and independent mechanisms. J Invest Dermatol 108:258-62
LeBlanc, N; Falabella, A; Murata, H et al. (1997) Durometer measurements of skin induration in venous disease. Dermatol Surg 23:285-7
Hasan, A; Murata, H; Falabella, A et al. (1997) Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1. J Dermatol Sci 16:59-66
Van de Scheur, M; Falanga, V (1997) Pericapillary fibrin cuffs in venous disease. A reappraisal. Dermatol Surg 23:955-9
Greenberg, A S; Hasan, A; Montalvo, B M et al. (1996) Acute lipodermatosclerosis is associated with venous insufficiency. J Am Acad Dermatol 35:566-8
Badiavas, E; Mehta, P P; Falanga, V (1996) Retrovirally mediated gene transfer in a skin equivalent model of chronic wounds. J Dermatol Sci 13:56-62
Helfman, T; Falanga, V (1995) Stanozolol as a novel therapeutic agent in dermatology. J Am Acad Dermatol 33:254-8

Showing the most recent 10 out of 20 publications